These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32870904)

  • 1. Correction: Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis.
    Birnie E; Koh GCKW; Löwenberg EC; Meijers JCM; Maude RR; Day NPJ; Peacock SJ; van der Poll T; Wiersinga WJ
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008722. PubMed ID: 32870904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis.
    Birnie E; Koh GC; Löwenberg EC; Meijers JC; Maude RR; Day NP; Peacock SJ; van der Poll T; Wiersinga WJ
    PLoS Negl Trop Dis; 2017 Mar; 11(3):e0005468. PubMed ID: 28296884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unbalanced expression of ADAMTS13 and von Willebrand factor in mouse endotoxinemia.
    Mimuro J; Niimura M; Kashiwakura Y; Ishiwata A; Ono T; Ohmori T; Madoiwa S; Okada K; Matsuo O; Sakata Y
    Thromb Res; 2008; 122(1):91-7. PubMed ID: 18006046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in von Willebrand factor and ADAMTS13 during IVF.
    Westerlund E; Antovic A; Hovatta O; Eberg KP; Blombäck M; Wallén H; Henriksson P
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):127-31. PubMed ID: 21192251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
    Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
    BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of von Willebrand factor and low levels of its cleaving protease, ADAMTS13, are associated with stroke in young HIV-infected patients.
    Allie S; Stanley A; Bryer A; Meiring M; Combrinck MI
    Int J Stroke; 2015 Dec; 10(8):1294-6. PubMed ID: 26121272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction: Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm.
    PLOS Neglected Tropical Diseases Staff
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003737. PubMed ID: 25901744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavior of ADAMTS13 and Von Willebrand factor levels in patients after living donor liver transplantation.
    Takahashi N; Wada H; Usui M; Kobayashi T; Habe-Ito N; Matsumoto T; Uemoto S; Nobori T; Isaji S
    Thromb Res; 2013 Mar; 131(3):225-9. PubMed ID: 23266519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: Evaluation of antigen-detecting and antibody-detecting diagnostic test combinations for diagnosing melioidosis.
    PLOS Neglected Tropical Diseases Staff
    PLoS Negl Trop Dis; 2022 Jun; 16(6):e0010095. PubMed ID: 35653655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.
    Dhanesha N; Prakash P; Doddapattar P; Khanna I; Pollpeter MJ; Nayak MK; Staber JM; Chauhan AK
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1829-37. PubMed ID: 27444201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
    Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
    Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study.
    Rutten B; Maseri A; Cianflone D; Laricchia A; Cristell NA; Durante A; Spartera M; Ancona F; Limite L; Hu D; Li H; Uren NG; de Groot PG; Mannucci PM; Roest M
    Eur Heart J Acute Cardiovasc Care; 2015 Feb; 4(1):64-74. PubMed ID: 24833640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased von Willebrand factor ristocetin cofactor activity and increased ADAMTS13 antigen increase postoperative drainage after coronary artery bypass grafting.
    Mazur P; Plicner D; Zdziarska J; Sadowski J; Undas A
    Eur J Cardiothorac Surg; 2014 Feb; 45(2):e26-32. PubMed ID: 24351199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.
    Molvarec A; Rigó J; Bõze T; Derzsy Z; Cervenak L; Makó V; Gombos T; Udvardy ML; Hársfalvi J; Prohászka Z
    Thromb Haemost; 2009 Feb; 101(2):305-11. PubMed ID: 19190814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure.
    Gombos T; Makó V; Cervenak L; Papassotiriou J; Kunde J; Hársfalvi J; Förhécz Z; Pozsonyi Z; Borgulya G; Jánoskuti L; Prohászka Z
    Thromb Haemost; 2009 Sep; 102(3):573-80. PubMed ID: 19718479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation.
    Reiter RA; Varadi K; Turecek PL; Jilma B; Knöbl P
    Thromb Haemost; 2005 Mar; 93(3):554-8. PubMed ID: 15735809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
    Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
    Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13].
    Zhang JY; Su J; Ma ZN; Dong NZ; Wang YC; Ruan CG
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):169-72. PubMed ID: 22781599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.